Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mirum Pharmaceuticals, Inc.

45.99
-0.0900-0.20%
Post-market: 45.990.00000.00%18:21 EDT
Volume:155.89K
Turnover:7.18M
Market Cap:2.25B
PE:-24.85
High:46.52
Open:46.44
Low:45.79
Close:46.08
Loading ...

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Zacks
·
Yesterday

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

MT Newswires Live
·
27 Mar

BRIEF-LIVMARLI Now Approved In Japan For ALGS And PFIC

Reuters
·
27 Mar

Livmarli NOW Approved in Japan for Algs and Pfic

THOMSON REUTERS
·
27 Mar

LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire
·
27 Mar

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.
·
25 Mar

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough

Simply Wall St.
·
21 Mar

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
11 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
03 Mar

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Simply Wall St.
·
01 Mar

Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Feb

Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $72 From $66

THOMSON REUTERS
·
28 Feb

Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
28 Feb

Evercore ISI Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
28 Feb

Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Zacks
·
27 Feb